Venmax Drugs and Pharmaceuticals PE ratio history and valuation
BSE: 531015Pharmaceuticals & BiotechnologySmall Cap
Venmax Drugs and Pharmaceuticals Ltd · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1995
Last close ₹12.97down ₹0.09 (0.69%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹13.06.
29 Oct: open ₹13.06, high ₹14.49, low ₹12.80
52-week range of traded prices to 29 Oct 2026
₹12.71Low, 17 Sep 2026₹31.49High, 3 Dec 2025
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15 Cr4,053rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Not shown: another business merged into the company on 30 Jun 2026, and the accounts this figure is made of do not include it yet. It returns once accounts of the company as it now is are filed. Price to book: how it is worked out
- Mergernew accounts awaited
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 17,154
Venmax Drugs and Pharmaceuticals' price to sales and dividend yield on 29 Oct 2026, each against its own history of up to a year. Its P/E is not shown: the figures it needs for the twelve months to Jun 2026 are not complete or not comparable.
Venmax Drugs and Pharmaceuticals PE ratio and valuation against its own history
- Price to earningsA results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
- Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.Merger, new accounts awaited
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.1.62today
1 year
Median 3.26Today is at or above 0.5% of the 217 days
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.Merger, new accounts awaited
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 246 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.A results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Price to sales =Market cap÷Revenue, last twelve monthsRevenue, last twelve months. Revenue from operations over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹9.29 Cr
- EV to EBITDA =Enterprise value÷Operating profit, last twelve monthsOperating profit, last twelve months. Profit before depreciation, interest and tax over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly).₹0.15 Cr
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.1,15,82,930at 30 Sep 2026
Standalone accounts, the twelve months to Jun 2026, ₹ crore.Venmax Drugs and Pharmaceuticals financials ›
Venmax Drugs and Pharmaceuticals valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2017 | Mar 2018 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Market cap (₹ crore)Market capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. | 1.6 | 2.2 | 14.9 | 20.6 |
| Price to earnings | Loss | Loss | Loss | 23.7 |
| Price to book | No balance sheet | No balance sheet | Negative net worth | Shares changed |
| Price to sales | 2.8 | Revenue not stated | 31.5 | 4.7 |
| EV to EBITDA | Operating profit not stated | Operating profit not stated | Operating loss | Operating loss |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings yield | −87.3% | −4.2% | −5.0% | 4.2% |
A ratio that does not exist on the day says why in its cell.
Venmax Drugs and Pharmaceuticals market cap, ten years
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Dividends and the public's market cap
From the close on 29 Oct 2026.
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹13 Cr
Against Pharmaceuticals
215 listed companies in Pharmaceuticals, each priced on its last trading day; Venmax Drugs and Pharmaceuticals is 206th among them by market cap. Each median leaves out Venmax Drugs and Pharmaceuticals itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.3Across 158 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 191 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.0Across 144 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.48%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Span DivergentSDL | 17 | – | 1.17 | – | 0.00% |
 Star Source Multi TradeSTARSOURCE | 17 | – | 12.91 | – | 0.00% |
| Mono PharmacareMONOPHARMA | 16 | 44.15 | 0.50 | – | 0.00% |
 Desh Rakshak AushdhalayaDESHRAK | 15 | 27.77 | 1.15 | 13.0 | 0.00% |
| Venmax Drugs and PharmaceuticalsVENMAX | 15 | – | – | – | 0.00% |
 Beryl DrugsBERLDRG | 13 | 20.30 | 1.28 | 8.2 | 0.00% |
 Unjha FormulationsUNJHAFOR | 12 | 25.81 | 3.17 | 14.3 | 0.00% |
 Ortin GlobalORTINGLOBE | 11 | – | 8.63 | – | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.